Program overview
Context
Indication: Advanced or Metastatic Breast Cancer
Mechanism: Unknown
Modality: Unknown
Sponsor: AstraZeneca
Low Signal
AZD5363 when combined with weekly paclitaxel.
AZD5363 when combined with weekly paclitaxel. is flagged as low signal because public records show limited public risk signal. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Scores
Risk-signal summary
Registry: 0/5
Timeline: 1/5
Recruitment burden: 1/5
Results availability: 0/5
Program risk: 1/5
Evidence
Public links
https://clinicaltrials.gov/study/NCT01625286
Linked trials
Trial-level signal details
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT01625286 | Low Signal (COMPLETED) | stale_update_signal | Low Signal | rare_population_signal |